The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families
Open accessAbstract
PURPOSE: To estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germline PALB2 pathogenic variants (PVs) because these risks have not been extensively characterized. METHODS: We analyzed data from 524 families with PALB2 PVs from 21 countries. Complex segregation analysis was used to estimate relative risks (RRs; relative to country-specific population incidences) and absolute risks of cancers. The models allowed for residual familial aggregation of breast and ovarian cancer and were adjusted for the family-specific ascertainment schemes. RESULTS: We found associations between PALB2 PVs and risk of female breast cancer (RR, 7.18; 95% CI, 5.82 to 8.85; P = 6.5 × 10−76), ovarian cancer (RR, 2.91; 95% CI, 1.40 to 6.04; P = 4.1 × 10−3), pancreatic cancer (RR, 2.37; 95% CI, 1.24 to 4.50; P = 8.7 × 10−3), and male breast cancer (RR, 7.34; 95% CI, 1.28 to 42.18; P = 2.6 × 10−2). There was no evidence for increased risks of prostate or colorectal cancer. The breast cancer RRs declined with age ( P for trend = 2.0 × 10−3). After adjusting for family ascertainment, breast cancer risk estimates on the basis of multiple case families were similar to the estimates from families ascertained through population-based studies ( P for difference = .41). On the basis of the combined data, the estimated risks to age 80 years were 53% (95% CI, 44% to 63%) for female breast cancer, 5% (95% CI, 2% to 10%) for ovarian cancer, 2%-3% (95% CI females, 1% to 4%; 95% CI males, 2% to 5%) for pancreatic cancer, and 1% (95% CI, 0.2% to 5%) for male breast cancer. CONCLUSION: These results confirm PALB2 as a major breast cancer susceptibility gene and establish substantial associations between germline PALB2 PVs and ovarian, pancreatic, and male breast cancers. These findings will facilitate incorporation of PALB2 into risk prediction models and optimize the clinical cancer risk management of PALB2 PV carriers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Self-citationRisks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K.-A., Mooij, T. M., Roos-Blom, M.-J., Jervis, S., van Leeuwen, F. E., Milne, R. L., Andrieu, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7112 · Cited by 2,954
Self-citationPALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene
The Breast Cancer Susceptibility Collaboration (UK), Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A., Reid, S., Spanova, K., Barfoot, R., et al. (2007) · Nature Genetics · doi:10.1038/ng1959 · Cited by 1,003
Self-citationWalsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A. M., Roeb, W., Agnew, K. J., Stray, S. M., Wickramanayake, A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115052108 · Cited by 933
Control of BRCA2 Cellular and Clinical Functions by a Nuclear Partner, PALB2
Xia, B., Sheng, Q., Nakanishi, K., Ohashi, A., Wu, J., Christ, N., Liu, X., Jasin, M., Couch, F. J., & Livingston, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.022 · Cited by 861
Self-citationBreast-Cancer Risk in Families with Mutations in PALB2
Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkäs, K., Roberts, J., Lee, A., Subramanian, D., De Leeneer, K., Fostira, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400382 · Cited by 851
Self-citationPathogenic Germline Variants in 10,389 Adult Cancers
Huang, K.-L., Mashl, R. J., Wu, Y., Ritter, D. I., Wang, J., Oh, C., Paczkowska, M., Reynolds, S., Wyczalkowski, M. A., Oak, N., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.039 · Cited by 833
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-H., Palmisano, E., Brune, K., Jaffee, E. M., et al. (2009) · Science · doi:10.1126/science.1171202 · Cited by 826 · cited 1×
“Previous observational studies of PALB2 in familial PaC reported conflicting results.(8,9,33-36) The current analysis confirms the association with PaC and is the first in our knowledge to quantify it, with an RR estimate of 2.”
ResultInherited Mutations in Women With Ovarian Carcinoma
Norquist, B. M., Harrell, M. I., Brady, M. F., Walsh, T., Lee, M. K., Gulsuner, S., Bernards, S. S., Casadei, S., Yi, Q., Burger, R. A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5495 · Cited by 769
Pearlman, R., Frankel, W. L., Swanson, B., Zhao, W., Yilmaz, A., Miller, K., Bacher, J., Bigley, C., Nelsen, L., Goodfellow, P. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5194 · Cited by 707
Programs for pedigree analysis: Mendel, Fisher, and dGene
Lange, K., Weeks, D., Boehnke, M., MacCluer, J. W., & MacCluer, J. W. (1988) · Genetic Epidemiology · doi:10.1002/gepi.1370050611 · Cited by 616
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array
Initiative, T. C. R. U. G. (. O. G.-O., Eeles, R. A., Bioresource, T. A. P. C., The UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology, Collaborators, T. U. P. (. T. F. C. A. T. S., The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Olama, A. A. A., Benlloch, S., Saunders, E. J., Leongamornlert, D. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2560 · Cited by 542
Self-citationThe BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions
Antoniou, A. C., Cunningham, A. P., Peto, J., Evans, D. G., Lalloo, F., Narod, S. A., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Southey, M. C., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604305 · Cited by 525
Self-citationCancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer
Yurgelun, M. B., Kulke, M. H., Fuchs, C. S., Allen, B. A., Uno, H., Hornick, J. L., Ukaegbu, C. I., Brais, L. K., McNamara, P. G., Mayer, R. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0012 · Cited by 524
A recurrent mutation in PALB2 in Finnish cancer families
Erkko, H., Xia, B., Nikkilä, J., Schleutker, J., Syrjäkoski, K., Mannermaa, A., Kallioniemi, A., Pylkäs, K., Karppinen, S.-M., Rapakko, K., et al. (2007) · Nature · doi:10.1038/nature05609 · Cited by 466
Self-citationGermline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer
Ramus, S. J., Song, H., Dicks, E., Tyrer, J. P., Rosenthal, A. N., Intermaggio, M. P., Fraser, L., Gentry-Maharaj, A., Hayward, J., Philpott, S., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv214 · Cited by 437
Self-citationKuchenbaecker, K. B., McGuffog, L., Barrowdale, D., Lee, A., Soucy, P., Dennis, J., Domchek, S. M., Robson, M., Spurdle, A. B., Ramus, S. J., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw302 · Cited by 327
Self-citationCounselling framework for moderate-penetrance cancer-susceptibility mutations
Tung, N., Domchek, S. M., Stadler, Z., Nathanson, K. L., Couch, F., Garber, J. E., Offit, K., & Robson, M. E. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.90 · Cited by 314
Self-citationBRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study
Zhen, D. B., Rabe, K. G., Gallinger, S., Syngal, S., Schwartz, A. G., Goggins, M. G., Hruban, R. H., Cote, M. L., McWilliams, R. R., Roberts, N. J., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.153 · Cited by 295
Antoniou, A. C., Pharoah, P. D. P., McMullan, G., Day, N. E., Ponder, B. A. J., & Easton, D. (2001) · Genetic Epidemiology · doi:10.1002/gepi.1014 · Cited by 289
Self-citationVariation of Breast Cancer Risk Among BRCA1/2 Carriers
Begg, C. B., Haile, R. W., Borg, Å., Malone, K. E., Concannon, P., Thomas, D. C., Langholz, B., Bernstein, L., Olsen, J. H., Lynch, C. F., et al. (2008) · JAMA · doi:10.1001/jama.2007.55-a · Cited by 279
Self-citationPALB2 mutations in European familial pancreatic cancer families
Slater, E., Langer, P., Niemczyk, E., Strauch, K., Butler, J., Habbe, N., Neoptolemos, J., Greenhalf, W., & Bartsch, D. (2010) · Clinical Genetics · doi:10.1111/j.1399-0004.2010.01425.x · Cited by 278
A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Castroviejo‐Bermejo, M., Cruz, C., Llop‐Guevara, A., Gutiérrez‐Enríquez, S., Ducy, M., Ibrahim, Y. H., Gris‐Oliver, A., Pellegrino, B., Bruna, A., Guzmán, M., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809172 · Cited by 268
Self-citationAscertainment in the sequential sampling of pedigrees
Cannings, C., & Thompson, E. A. (1977) · Clinical Genetics · doi:10.1111/j.1399-0004.1977.tb00928.x · Cited by 241
Validation of family history data in cancer family registries
Ziogas, A., & Anton-Culver, H. (2003) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(02)00593-7 · Cited by 240
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS
Southey, M. C., Goldgar, D. E., Winqvist, R., Pylkäs, K., Couch, F., Tischkowitz, M., Foulkes, W. D., Dennis, J., Michailidou, K., van Rensburg, E. J., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-103839 · Cited by 213
Self-citationAnalysis of PALB2/FANCN-associated breast cancer families
Tischkowitz, M., Xia, B., Sabbaghian, N., Reis-Filho, J. S., Hamel, N., Li, G., van Beers, E. H., Li, L., Khalil, T., Quenneville, L. A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701724104 · Cited by 211
Self-citationOn the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance
Begg, C. B. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1221 · Cited by 201
Tischkowitz, M. D., Sabbaghian, N., Hamel, N., Borgida, A., Rosner, C., Taherian, N., Srivastava, A., Holter, S., Rothenmund, H., Ghadirian, P., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.055 · Cited by 189
Self-citationLevy-Lahad, E., Lahad, A., Eisenberg, S., Dagan, E., Paperna, T., Kasinetz, L., Catane, R., Kaufman, B., Beller, U., Renbaum, P., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051624098 · Cited by 182
Lu, H.-M., Li, S., Black, M. H., Lee, S., Hoiness, R., Wu, S., Mu, W., Huether, R., Chen, J., Sridhar, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2956 · Cited by 178
Self-citationSahasrabudhe, R. M., Lott, P. C., Bohorquez, M., Toal, T., Estrada-Florez, A. P., Suárez, J. J., Brea‐Fernández, A., Cameselle‐Teijeiro, J., Pinto, C., Ramos, I., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.12.010 · Cited by 132
Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States
Ding, Y. C., Steele, L., Kuan, C.-J., Greilac, S., & Neuhausen, S. L. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1195-2 · Cited by 130
Self-citationInherited DNA-Repair Defects in Colorectal Cancer
AlDubayan, S. H., Giannakis, M., Moore, N. D., Han, G. C., Reardon, B. M., Hamada, T., Mu, X. J., Nishihara, R., Qian, Z., Liu, L., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.01.018 · Cited by 124
A resolution of the ascertainment sampling problem I. Theory
Ewens, W. J., & Shute, N. C. E. (1986) · Theoretical Population Biology · doi:10.1016/0040-5809(86)90042-0 · Cited by 114
Fewings, E., Larionov, A. A., Redman, J., Goldgraben, M. A., Scarth, J. A., Richardson, S., Brewer, C., Davidson, R., Ellis, I., Evans, D. G., et al. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30079-7 · Cited by 113
Self-citationThe Tumor Suppressor PALB2: Inside Out
Ducy, M., Sesma-Sanz, L., Guitton-Sert, L., Lashgari, A., Gao, Y., Brahiti, N., Rodrigue, A., Margaillan, G., Caron, M., Côté, J., et al. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.10.008 · Cited by 105
Taylor, A., Brady, A. F., Frayling, I. M., Hanson, H., Tischkowitz, M. D., Turnbull, C., & Side, L. E. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2017-105188 · Cited by 102
Self-citationCompromised BRCA1–PALB2 interaction is associated with breast cancer risk
Foo, T. K., Tischkowitz, M. D., Simhadri, S. R., Boshari, T., Zayed, N., Burke, K. A., Berman, S. H., Blecua, P., Riaz, N., Huo, Y., et al. (2017) · Oncogene · doi:10.1038/onc.2017.46 · Cited by 87
Self-citationRizzolo, P., Zelli, V., Silvestri, V., Valentini, V., Zanna, I., Bianchi, S., Masala, G., Spinelli, A. M., Tibiletti, M. G., Russo, A. D., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32106 · Cited by 58
Self-citationBlanco, A., de la Hoya, M., Balmañà, J., y Cajal, T. R., Teulé, À., Miramar, M.-D., Esteban, E., Infante, M., Benitez, J. J., Torres, A., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1842-2 · Cited by 57
Harinck, F., Kluijt, I., van Mil, S. E., Waisfisz, Q., van Os, T. A. M., Aalfs, C. M., Wagner, A., Olderode-Berends, M. J. W., Sijmons, R. H., Kuipers, E. J., et al. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.226 · Cited by 42
Analysis of the gene coding for the BRCA2‐Interacting protein PALB2 in hereditary prostate cancer
Tischkowitz, M. D., Sabbaghian, N., Ray, A. M., Lange, E. M., Foulkes, W. D., & Cooney, K. A. (2008) · The Prostate · doi:10.1002/pros.20729 · Cited by 41
Self-citationGrant, R. C., Al-Sukhni, W., Borgida, A., Holter, S., Kanji, Z. S., McPherson, T. A., Whelan, E. R., Serra, S., Trinh, Q. M., Peltekova, V. D., et al. (2013) · Human Genomics · doi:10.1186/1479-7364-7-11 · Cited by 37
Change in the penetrance of founder BRCA1/2 mutations? A retrospective cohort study
Foulkes, W. D., Brunet, J.-S., Wong, N., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.6.407 · Cited by 13
Self-citation
Cited by
Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Miller, D. T., Lee, K., Chung, W. K., Gordon, A. S., Herman, G. E., Klein, T. E., Stewart, D. R., Amendola, L. M., Adelman, K., Bale, S. J., et al. (2021) · Genetics in Medicine · doi:10.1038/s41436-021-01172-3 · Cited by 535
Tung, N. M., Robson, M. E., Ventz, S., Santa-Maria, C. A., Nanda, R., Marcom, P. K., Shah, P. D., Ballinger, T. J., Yang, E. S., Vinayak, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02151 · Cited by 508
Self-citationStoop, T. F., Javed, A. A., Oba, A., Koerkamp, B. G., Seufferlein, T., Wilmink, J. W., & Besselink, M. G. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00261-2 · Cited by 479
Sessa, C., Balmaña, J., Bober, S. L., Cardoso, M. J., Colombo, N., Curigliano, G., Domchek, S. M., Evans, D. G., Fischerova, D., Harbeck, N., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.004 · Cited by 295
Self-citation
Metadata
- Authors
- Yang, X., Leslie, G., Doroszuk, A., Schneider, S., Allen, J., Decker, B., Dunning, A. M., Redman, J., Scarth, J., Plaskocinska, I., Luccarini, C., Shah, M., Pooley, K., Dorling, L., Lee, A., Adank, M. A., Adlard, J., Aittomäki, K., Andrulis, I. L., Ang, P., Barwell, J., Bernstein, J. L., Bobolis, K., Borg, Å., Blomqvist, C., Claes, K. B. M., Concannon, P., Cuggia, A., Culver, J. O., Damiola, F., de Pauw, A., Diez, O., Dolinsky, J. S., Domchek, S. M., Engel, C., Evans, D. G., Fostira, F., Garber, J., Golmard, L., Goode, E. L., Gruber, S. B., Hahnen, E., Hake, C., Heikkinen, T., Hurley, J. E., Janavicius, R., Kleibl, Z., Kleiblova, P., Konstantopoulou, I., Kvist, A., Laduca, H., Lee, A. S. G., Lesueur, F., Maher, E. R., Mannermaa, A., Manoukian, S., McFarland, R., McKinnon, W., Meindl, A., Metcalfe, K., Mohd Taib, N. A., Moilanen, J., Nathanson, K. L., Neuhausen, S., Ng, P. S., Nguyen-Dumont, T., Nielsen, S. M., Obermair, F., Offit, K., Olopade, O. I., Ottini, L., Penkert, J., Pylkäs, K., Radice, P., Ramus, S. J., Rudaitis, V., Side, L., Silva-Smith, R., Silvestri, V., Skytte, A.-B., Slavin, T., Soukupova, J., Tondini, C., Trainer, A. H., Unzeitig, G., Usha, L., van Overeem Hansen, T., Whitworth, J., Wood, M., Yip, C. H., Yoon, S.-Y., Yussuf, A., Zogopoulos, G., Goldgar, D., Hopper, J. L., Chenevix-Trench, G., Pharoah, P., George, S. H. L., Balmaña, J., Houdayer, C., James, P., El-Haffaf, Z., Ehrencrona, H., Janatova, M., Peterlongo, P., Nevanlinna, H., Schmutzler, R., Teo, S.-H., Robson, M., Pal, T., Couch, F., Weitzel, J. N., Elliott, A., Southey, M., Winqvist, R., Easton, D. F., Foulkes, W. D., Antoniou, A. C., & Tischkowitz, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-03-01
- Volume
- 38
- Issue
- 7
- Pages
- 674-685
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2989421973
- Cited by
- 432
- References
- 46
- FWCI
- 25.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.